5:53 PM
 | 
Nov 07, 2013
 |  BC Extra  |  Clinical News

Merrimack gains on MM-398 trial update

Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) rose $0.50 (24%) to $2.56 on Thursday after disclosing in its 3Q13 financial results that because overall survival (OS) events are "occurring later than forecasted" it does not expect...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >